Content Navigation
( All
None )
Target General Information |
Top |
Target ID |
T98052 |
Target Info
|
Target Name |
SLAM family member 7 SLAMF7 (CS1) |
Synonyms |
UNQ576/PRO1138; SLAM family member 7; Protein 19A; Novel Ly9; Membrane protein FOAP-12; CRACC; CD319; CD2-like receptor-activating cytotoxic cells; CD2 subset 1 |
Target Type |
Successful Target |
Gene Name |
SLAMF7 |
Biochemical Class |
Immunoglobulin |
UniProt ID |
|
Targeted Antigens of CAR-T Cell Therapy |
Top |
CAR T-Cell Therapy Drug(s) |
BCMA-CS1 cCAR |
Drug Info
|
Phase 1 |
Multiple myeloma |
[1] |
CS1-CAR T Therapy |
Drug Info
|
Phase 1 |
Plasma cell myeloma |
[2] |
MB-104 |
Drug Info
|
Phase 1 |
Multiple myeloma |
[3] |
UCARTCS1 |
Drug Info
|
Phase 1 |
Multiple myeloma |
[4] |
References |
Top |
REF 1 |
ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
|
REF 2 |
ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
REF 3 |
ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma. U.S. National Institutes of Health.
|
REF 4 |
ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.